DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 12, 2008, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:
Drug
Schedule
Cathinone (1235)
I
Methcathinone (1237)
I
Aminorex (1585)
I
Alpha-ethyltryptamine (7249)
I
Lysergic acid diethylamide (7315)
I
Tetrahydrocannabinols (7370)
I
4-Bromo-2,5-dimethoxy-amphetamine (7391)
I
4-Bromo-2,5-dimethoxyphenethylamine (7392)
I
2,5-Dimethoxyamphetamine (7396)
I
3,4-Methylenedioxyamphetamine (7400)
I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
I
3,4-Methylenedioxy-N-ethylamphetamine (7404)
I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)
I
Psilocybin (7437)
I
5-Methoxy-N,N-diisopropyltryptamine (7439)
I
1-[1-(2-Thienyl) cyclohexyl] piperidine (TCP) (7470)
I
1-Benzylpiperazine (BZP) (7493)
I
Heroin (9200)
I
Normorphine (9313)
I
Amphetamine (1100)
II
Methamphetamine (1105)
II
Nabilone (7379)
II
1-Phenylcyclohexylamine (7460)
II
Phencyclidine (7471)
II
Cocaine (9041)
II
Codeine (9050)
II
Diprenorphine (9058)
II
Ecgonine (9180)
II
Levomethorphan (9210)
II
Levorphanol (9220)
II
Meperidine (9230)
II
Metazocine (9240)
II
Methadone (9250)
II
Morphine (9300)
II
Thebaine (9333)
II
Levo-alphacetylmethadol (9648)
II
Carfentanil (9743)
II
Fentanyl (9801)
II
The company plans to manufacture reference standards.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 27, 2008.
Dated: March 19, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.